Melanoma

Board recommends continuations of Canvaxin phase III trial

Published in Cancer Vaccine Week, April 5th, 2004

CancerVax Corporation (CNVX) announced that an independent Data and Safety Monitoring Board (DSMB) completed its planned, second, interim analysis of the company's randomized, double-blind, international phase III clinical trial of its investigational immunotherapy, Canvaxin, for the treatment of patients with stage III melanoma.

The DSMB recommended that CancerVax continue the trial as planned.

This recommendation means that, in the opinion of the DSMB, there is a reasonable likelihood that clinical endpoints can be met to establish the effectiveness of Canvaxin, and that there are no unexpected or serious toxicities associated with the product...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Vaccine Week

Source: Cancer Vaccine Week (2004-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry